Name | Number of supported studies | Average coverage | |
---|---|---|---|
pericyte | 6 studies | 29% ± 14% | |
interneuron | 5 studies | 22% ± 3% | |
macrophage | 5 studies | 29% ± 11% | |
endothelial cell | 4 studies | 42% ± 17% | |
hematopoietic precursor cell | 3 studies | 31% ± 13% | |
astrocyte | 3 studies | 41% ± 9% | |
neuron | 3 studies | 28% ± 12% | |
B cell | 3 studies | 35% ± 14% | |
GABAergic neuron | 3 studies | 24% ± 6% | |
hematopoietic stem cell | 3 studies | 25% ± 7% | |
platelet | 3 studies | 20% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 90% | 34.65 | 523 / 578 | 62% | 7.50 | 714 / 1155 |
esophagus | 53% | 87.38 | 773 / 1445 | 77% | 10.03 | 140 / 183 |
pancreas | 56% | 51.31 | 184 / 328 | 46% | 2.44 | 82 / 178 |
intestine | 65% | 18.22 | 628 / 966 | 32% | 2.41 | 168 / 527 |
skin | 34% | 653.14 | 623 / 1809 | 50% | 3.98 | 238 / 472 |
thymus | 78% | 27.69 | 511 / 653 | 3% | 0.77 | 19 / 605 |
stomach | 35% | 6.65 | 126 / 359 | 41% | 3.90 | 117 / 286 |
tonsil | 0% | 0 | 0 / 0 | 64% | 6.16 | 29 / 45 |
peripheral blood | 61% | 407.67 | 564 / 929 | 0% | 0 | 0 / 0 |
spleen | 61% | 13.47 | 146 / 241 | 0% | 0 | 0 / 0 |
adipose | 58% | 14.83 | 704 / 1204 | 0% | 0 | 0 / 0 |
uterus | 13% | 2.42 | 22 / 170 | 45% | 3.90 | 207 / 459 |
lymph node | 0% | 0 | 0 / 0 | 55% | 5.38 | 16 / 29 |
ovary | 13% | 3.93 | 23 / 180 | 37% | 4.32 | 161 / 430 |
bladder | 5% | 0.57 | 1 / 21 | 33% | 2.51 | 165 / 504 |
breast | 32% | 6.57 | 147 / 459 | 5% | 0.36 | 54 / 1118 |
brain | 9% | 1.69 | 226 / 2642 | 26% | 1.94 | 181 / 705 |
liver | 6% | 1.22 | 14 / 226 | 20% | 1.31 | 83 / 406 |
kidney | 11% | 2.10 | 10 / 89 | 11% | 0.68 | 101 / 901 |
prostate | 20% | 4.20 | 48 / 245 | 0% | 0.00 | 1 / 502 |
blood vessel | 18% | 4.02 | 246 / 1335 | 0% | 0 | 0 / 0 |
adrenal gland | 10% | 1.69 | 27 / 258 | 2% | 0.09 | 5 / 230 |
heart | 3% | 0.58 | 25 / 861 | 0% | 0 | 0 / 0 |
muscle | 2% | 0.48 | 13 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0009653 | Biological process | anatomical structure morphogenesis |
GO_0006412 | Biological process | translation |
GO_0051028 | Biological process | mRNA transport |
GO_0007399 | Biological process | nervous system development |
GO_0001817 | Biological process | regulation of cytokine production |
GO_0017148 | Biological process | negative regulation of translation |
GO_0070934 | Biological process | CRD-mediated mRNA stabilization |
GO_0000932 | Cellular component | P-body |
GO_0005829 | Cellular component | cytosol |
GO_0010494 | Cellular component | cytoplasmic stress granule |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0045182 | Molecular function | translation regulator activity |
GO_0003730 | Molecular function | mRNA 3'-UTR binding |
GO_0048027 | Molecular function | mRNA 5'-UTR binding |
GO_0005515 | Molecular function | protein binding |
GO_1990247 | Molecular function | N6-methyladenosine-containing RNA reader activity |
GO_0003723 | Molecular function | RNA binding |
Gene name | IGF2BP3 |
Protein name | Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2 mRNA-binding protein 3) (IMP-3) (IGF-II mRNA-binding protein 3) (KH domain-containing protein overexpressed in cancer) (hKOC) (VICKZ family member 3) Insulin like growth factor 2 mRNA binding protein 3 |
Synonyms | KOC1 VICKZ3 IMP3 |
Description | FUNCTION: RNA-binding factor that may recruit target transcripts to cytoplasmic protein-RNA complexes (mRNPs). This transcript 'caging' into mRNPs allows mRNA transport and transient storage. It also modulates the rate and location at which target transcripts encounter the translational apparatus and shields them from endonuclease attacks or microRNA-mediated degradation. Preferentially binds to N6-methyladenosine (m6A)-containing mRNAs and increases their stability . Binds to the 3'-UTR of CD44 mRNA and stabilizes it, hence promotes cell adhesion and invadopodia formation in cancer cells. Binds to beta-actin/ACTB and MYC transcripts. Increases MYC mRNA stability by binding to the coding region instability determinant (CRD) and binding is enhanced by m6A-modification of the CRD . Binds to the 5'-UTR of the insulin-like growth factor 2 (IGF2) mRNAs. . |
Accessions | ENST00000258729.8 [O00425-1] ENST00000421467.6 F8WD15 O00425 ENST00000619562.4 [O00425-2] |